http://ipkitten.blogspot.com/2025/05/commercial-success-is-nothing-burger.html
In recent years, Novo Nordisk’s weight loss drug semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, has become a pharmaceutical phenomenon. As with most successful pharmaceutical products, the remarkable success of semaglutide means we can also expect some high profile IP disputes. In jurisdictions lacking provisions for patent term extension, semaglutide is
Content reproduced from The IPKat as permitted under the Creative Commons Licence (UK).
